(Q34602577)

3 August 2017

1 reference

title

Selective targeting of T cell subsets: focus on alefacept - a remittive therapy for psoriasis (English)

1 reference

3 August 2017

Gerald G Krueger

1

1 reference

PubMed ID

11955280

3 August 2017

language of work or name

English

0 references

publication date

1 April 2002

1 reference

Expert Opinion on Biological Therapy

3 August 2017

1 reference

3 August 2017

2

1 reference

3 August 2017

4

1 reference

3 August 2017

431-441

1 reference

Effects of administration of a single dose of a humanized monoclonal antibody to CD11a on the immunobiology and clinical activity of psoriasis

3 August 2017

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

Psoriasis--epidemiology and clinical spectrum

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

Treatment of psoriasis. Part 1. Topical therapy and phototherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

Treatment of psoriasis. Part 2. Systemic therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

PUVA bath therapy strongly suppresses immunological and epidermal activation in psoriasis: a possible cellular basis for remittive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

Oral psoralen and ultraviolet-A light (PUVA) treatment of psoriasis and persistent risk of nonmelanoma skin cancer. PUVA Follow-up Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

The risk of melanoma in association with long-term exposure to PUVA.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

The practical use of methotrexate in psoriasis

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

Therapeutic strategies for psoriasis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

Duration of remission of psoriasis therapies

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

Psoriasis: current perspectives with an emphasis on treatment

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

Inflammatory skin diseases, T cells, and immune surveillance

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

Specific interaction of lymphocyte function-associated antigen 3 with CD2 can inhibit T cell responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

Treatment of chronic plaque psoriasis by selective targeting of memory effector T lymphocytes.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

Flow cytometric characterization of lesional T cells in psoriasis: intracellular cytokine and surface antigen expression indicates an activated, memory/effector type 1 immunophenotype.

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

The majority of epidermal T cells in Psoriasis vulgaris lesions can produce type 1 cytokines, interferon-gamma, interleukin-2, and tumor necrosis factor-alpha, defining TC1 (cytotoxic T lymphocyte) and TH1 effector populations: a type 1 differentiat

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

The pathogenesis of psoriasis: immunological facts and speculations

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

The immune system. First of two parts

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

Immunologic responses to bacteriophage ϕX 174 in immunodeficiency diseases

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

CTLA4Ig-mediated blockade of T-cell costimulation in patients with psoriasis vulgaris

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

Vascular leak syndrome: a side effect of immunotherapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

Clinical implications of dysregulated cytokine production

21 January 2018

1 reference

https://api.crossref.org/works/10.1517%2F14712598.2.4.431

21 January 2018

Identifiers

DOI

10.1517/14712598.2.4.431

1 reference

3 August 2017

1 reference

PubMed ID

11955280